Delving into the Latest Updates on Zensun (Shanghai) Sci & Tech Co., Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Cardiovascular Diseases

Infectious Diseases

AAV based gene therapy

Recombinant polypeptide

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Monoclonal antibody	1
AAV based gene therapy	1
Enzyme	1
Recombinant polypeptide	1

Top 5 Target	Count

NRG1(Neuregulin-1)	1
VDR(Vitamin D receptor)	1

[Translation] A phase III clinical trial of multicenter, randomized, double-blind, placebo-controlled parallel-group study based on standard treatment to evaluate the effects of recombinant human neuregulin for injection on cardiac function and reversal of ventricular remodeling in patients with chronic systolic heart failure

评价注射用重组人纽兰格林对男性 NT-proBNP ≤ 1700 pg/ml 以及女性 NT-proBNP ≤ 4000 pg/ml，纽约心功能分级 II-III 级慢性收缩性心力衰竭患者的心功能及逆转心室重构的影响，确证其疗效和安全性。

[Translation]

To evaluate the effects of recombinant human neuregulin for injection on cardiac function and reverse ventricular remodeling in patients with chronic systolic heart failure (NT-proBNP ≤ 1700 pg/ml in males and NT-proBNP ≤ 4000 pg/ml in females) and New York Heart Association functional class II-III, and to confirm its efficacy and safety.

Start Date04 May 2023

Sponsor / Collaborator

Zensun (Shanghai) Sci & Tech Co., Ltd.

NCT05949801 / RecruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Based on Standard Treatment to Evaluate the Effect of Injectable Neucardin on Cardiac Function and Reverse Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the effect of recombinant human Neuregulin-1 for injection on cardiac function and reverse ventricular remodeling in male patients with NT-proBNP ≤ 1700 pg/ml and female patients with NT-proBNP ≤ 4000 pg/ml and New York Heart Association class II-III chronic systolic heart failure, and to confirm its efficacy and safety.

Start Date13 Apr 2023

Sponsor / Collaborator

Zensun (Shanghai) Sci & Tech Co., Ltd.

CTR20192276 / RecruitingPhase 2

随机、双盲、安慰剂平行对照评价注射用重组人纽兰格林对射血分数保留心力衰竭(HFpEF) 患者安全性和有效性临床试验

[Translation] A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of recombinant human neuregulin for injection in patients with heart failure with preserved ejection fraction (HFpEF)

随机、双盲、安慰剂平行对照评估注射用重组人纽兰格林对射血分数保留心力衰竭患者(LVEF≥50%)的疗效，并进行安全性评价。

[Translation]

A randomized, double-blind, placebo-controlled parallel study was conducted to evaluate the efficacy of recombinant human neuregulin for injection in patients with heart failure with preserved ejection fraction (LVEF ≥ 50%) and to assess its safety.

Start Date03 Nov 2022

Sponsor / Collaborator

Zensun (Shanghai) Sci & Tech Co., Ltd.

100 Clinical Results associated with Zensun (Shanghai) Sci & Tech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zensun (Shanghai) Sci & Tech Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Zensun (Shanghai) Sci & Tech Co., Ltd.

01 Jul 2023·American journal of cardiovascular drugs : drugs, devices, and other interventions

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects.

Article

Author: Cui, Yimin ; Meng, Lei ; Sun, Peihong ; Zhou, Mingdong ; Zhao, Xia ; Wang, Xiaorui ; Zhou, Ying ; Qin, Xiaoyan ; Xu, Junyu

BACKGROUNDWe investigated the safety, tolerability, and pharmacokinetics of intravenous recombinant human Neuregulin-1 (rhNRG-1), a DNA recombinant protein for the treatment of chronic heart failure, in healthy Chinese volunteers following single and multiple dose administration.METHODS AND RESULTSTo evaluate the safety and tolerance after single-dosing escalation, 28 subjects were divided into six groups (0.2, 0.4, 0.8, 1.2, 1.6, and 2.4 μg/kg) to receive an intravenous (IV) infusion of rhNRG-1 over 10 min by a randomized, open-label design. Only the 1.2 μg/kg dose group obtained pharmacokinetic parameters: C_max was 7.645 (24.21) ng/mL, AUC_0-t was 97.088 (21.41) min·ng/mL. To assess the safety and pharmacokinetics after multiple-dosing, 32 subjects were divided into four groups (0.2, 0.4, 0.8, and 1.2 μg/kg) to receive a 10-min IV infusion of rhNRG-1 for five consecutive days. After multiple dosing of 1.2 μg/kg, the C_max value at day 5 was 8.838 (51.6) ng/mL and the AUC_0-t value at day 5 was 109.890 (32.99) min·ng/mL. RhNRG-1 is rapidly cleared from the blood and has a short t_1/2 of about 10 min. The adverse events related to rhNRG-1 mainly included flat or inverted T wave and gastrointestinal reactions, all of which were mild.CONCLUSIONSIt is concluded that rhNRG-1 is safe and well tolerated in healthy Chinese subjects at the dosing levels used in this study. The severity and frequency of adverse events did not increase with the prolongation of administration time.CLINICAL TRIAL REGISTRATIONChinese Clinical Trial Registry ( http://www.chictr.org.cn ) Identifier No. ChiCTR2000041107.

Zhonghua Gaoxueya Zazhi

Cell therapy for heart failure

Author: Tang, Tong

A review.Heart failure remains a disorder with unacceptably high morbidity and mortality.Recent development in cell therapy ignites new hopes for functional regeneration of the diseased heart.Despite the encouraging results from preclin. studies and clin. trials, many more detailed studies need to be performed before cell therapy can be transitioned for clin. use.This review summarizes important findings in the field of cell therapy for heart failure.

100 Deals associated with Zensun (Shanghai) Sci & Tech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zensun (Shanghai) Sci & Tech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

IND Application

Phase 2 Clinical

1

Phase 3 Clinical

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human neuregulin-1 (Zensun (Shanghai)) ( NRG1 )	Chronic heart failure More	Phase 3
Colecalciferol ( VDR )	Lower urinary tract infectious disease More	Phase 2
ZS-07	Alzheimer Disease More	IND Application
ZS-05	Urinary Tract Infections More	Preclinical
rAAV9 cMLCK	Heart Failure More	Preclinical